This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mall, V. Articles by Korinthenberg, R. Search for Related Content PubMed PubMed Citation Articles by Mall, V. Articles by Korinthenberg, R. Social Bookmarking                         What's this?

Evaluation of Botulinum Toxin A Therapy in Children With Adductor Spasm by Gross Motor Function Measure

Department of Neuropediatrics and Muscular Disorders, Children's Hospital, University of Freiburg

Florian Heinen, MD

Department of Neuropediatrics and Muscular Disorders, Children's Hospital, University of Freiburg, heinen{at}kkl200.ukl.uni-freiburg.de

Janbernd Kirschner, MD

Department of Neuropediatrics and Muscular Disorders, Children's Hospital, University of Freiburg

Michaela Linder, MD

Department of Neuropediatrics and Muscular Disorders, Children's Hospital, University of Freiburg

Sabine Stein, PT

Department of Neuropediatrics and Muscular Disorders, Children's Hospital, University of Freiburg

Ulla Michaelis, PT

Department of Neuropediatrics and Muscular Disorders, Children's Hospital, University of Freiburg

Peter Bernius, MD

Department of Orthopedics, University of Freiburg Germany

Mary Lane, PT

Neurodevelopmental Clinical Research Unit, West, McMaster University Hamilton, Canada

Rudolf Korinthenberg, MD

Department of Neuropediatrics and Muscular Disorders, Children's Hospital, University of Freiburg

Intramuscular injection of botulinum neurotoxin A is a relatively new method for treating spastic movement disorders in children. One major goal of any therapy for patients with movement disorders is to improve gross motor function. In this study, 18 patients with adductor spasm were treated with botulinum neurotoxin A. Treatment effect was determined with the Gross Motor Function Measure, a standardized, validated instrument designed to assist in assessment of gross motor function. Spastic muscle hyperactivity and joint mobility were evaluated by the modified Ashworth Scale and by range of motion, respectively. Compared to pretreatment values, significant improvement in gross motor function ( P < .010), decrease in the modified Ashworth Scale, and increase in the range of motion (P < .010) were achieved. Patients with moderate impairment of gross motor function (classed at level III and level IV in the Gross Motor Function Classification System) benefited most from treatment. In patients with severe handicap (level V), only one of five treated patients showed improvement in gross motor function. Nevertheless, all patients in this subgroup benefited from improved ease in hygienic care. In conclusion, we have demonstrated that for most children with moderate functional impairment, the Gross Motor Function Measure is a useful instrument for objective documentation of improvements of gross motor function following treatment with botulinum neurotoxin A. (J Child Neurol 2000;15:214-217).

Journal of Child Neurology, Vol. 15, No. 4, 214-217 (2000)
DOI: 10.1177/088307380001500402


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. K. Graham, R. Boyd, J. B. Carlin, F. Dobson, K. Lowe, G. Nattrass, P. Thomason, R. Wolfe, and D. Reddihough Does Botulinum Toxin A Combined with Bracing Prevent Hip Displacement in Children with Cerebral Palsy and "Hips at Risk"? A Randomized, Controlled Trial J. Bone Joint Surg. Am., January 1, 2008; 90(1): 23 - 33. [Abstract] [Full Text] [PDF]

				T. Pountney and E. M Green Hip dislocation in cerebral palsy. BMJ, April 1, 2006; 332(7544): 772 - 775. [Full Text] [PDF]

				K. W Nolan, L. L Cole, and G. S Liptak Use of Botulinum Toxin Type A in Children With Cerebral Palsy Physical Therapy, April 1, 2006; 86(4): 573 - 584. [Full Text] [PDF]

				A. H. Tilton Injectable Neuromuscular Blockade in the Treatment of Spasticity and Movement Disorders J Child Neurol, January 1, 2003; 18(1_suppl): S50 - S66. [Abstract] [PDF]

				P. Rosenbaum Controversial Treatment of Spasticity: Exploring Alternative Therapies for Motor Function in Children With Cerebral Palsy J Child Neurol, January 1, 2003; 18(1_suppl): S89 - S94. [Abstract] [PDF]

				P. L. Rosenbaum, S. D. Walter, S. E. Hanna, R. J. Palisano, D. J. Russell, P. Raina, E. Wood, D. J. Bartlett, and B. E. Galuppi Prognosis for Gross Motor Function in Cerebral Palsy: Creation of Motor Development Curves JAMA, September 18, 2002; 288(11): 1357 - 1363. [Abstract] [Full Text] [PDF]

				J. W. Gorter, P. L Rosenbaum, and M. Ketelaar Reanalyzing the Data Physical Therapy, August 1, 2002; 82(8): 828 - 830. [Full Text]